Expression of anergy markers on CD8+ TILs are downregulated following IFN-α2, IFN-γ and IL-2 treatments.

<p>Mice bearing subcutaneous B16.OVA tumors were injected with 2x10⁶ CD8a⁺ enriched OT-I lymphocytes into peritoneal cavity and beginning on the same day, tumors were injected with either PBS or recombinant cytokine in PBS or left non-injected (n = 5). Proportion of CD3⁺ CD8⁺ TILs expressing surface anergy markers (a) CTLA-4 and (b) PD-1 was analyzed by flow cytometry on day 14 post-transfer. Data presented as mean ± SEM. *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001 by one-way ANOVA followed by Tukey’s post-hoc test.